Takenori Uehara

Takenori Uehara

Auto-generated profile, based on publicly available information

Takenori Uehara

Department of Orthopaedic Surgery, NHO Okayama Medical Center, 1711-1 Tamasu, Kita-ku, Okayama 701-1192, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in EBioMedicine
Verified
Journal Article
Open access
YKYuki Kunisada
Yuki Kunisada
SEShingo Eikawa
Shingo Eikawa
NTNahoko Tomonobu
Nahoko Tomonobu
SDShohei Domae
Shohei Domae
TUTakenori Uehara
Takenori Uehara
HUHeiichiro Udono
Heiichiro Udono
CD4+CD25+ regulatory T cells (Treg), an essential subset for preventing autoimmune diseases, is implicated as a negative regulator in anti-tumor immunity. We found that metformin (Met) reduced tumor-infiltrating Treg (Ti-Treg), particularly the terminally-differentiated CD103+KLRG1+ population, and also decreased effector molecules such as CTLA4 and IL-10. Met inhibits the differentiation of naïve CD4+ T cells into inducible Treg (iTreg) by reducing forkhead box P3 (Foxp3) protein, caused by mTORC1 activation that was determined by the elevation of phosphorylated S6 (pS6), a downstream molecule of mTORC1. Rapamycin and compound C, an inhibitor of AMP-activated protein kinase (AMPK) restored the iTreg generation, further indicating the involvement of mTORC1 and AMPK. The metabolic profile of iTreg, increased Glut1-expression, and reduced mitochondrial membrane-potential and ROS production of Ti-Treg aided in identifying enhanced glycolysis upon Met-treatment. The negative impact of Met on Ti-Treg may help generation of the sustained antitumor immunity.

15 December 2018 in International Immunology
Verified
Journal Article
Open access
PDF file
TUTakenori Uehara
Takenori Uehara
SEShingo Eikawa
Shingo Eikawa
MNMikako Nishida
Mikako Nishida
YKYuki Kunisada
Yuki Kunisada
AYAki Yoshida
Aki Yoshida
Heiichiro  UdonoHeiichiro Udono
Heiichiro Udono
CD11b+ myeloid subpopulations, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), play crucial roles in the suppression of T-cell-mediated anti-tumor immunity. Regulation of these cell types is a primary goal for achieving efficient cancer immunotherapy. We found that metformin (Met) induces CD11b+-cell-mediated growth inhibition of a K7M2neo osteosarcoma independent of T cells, as growth inhibition of K7M2neo was still observed in wild-type (WT) mice depleted of T cells by antibodies and in SCID; this contrasted with the effect of Met on Meth A fibrosarcoma, which was entirely T-cell-dependent. Moreover, the inhibitory effect seen in SCID was abrogated by anti-CD11b antibody injection. PMN-MDSCs were significantly reduced in both spleens and tumors following Met treatment. In TAMs, production of IL-12 and TNF-α, but not IL-10, became apparent, and elevation of MHC class II with reduction of CD206 was observed, indicating a shift from an M2- to M1-like phenotype via Met administration. Metabolically, Met treatment decreased basal respiration and the oxygen consumption rate (OCR)/extracellular acidification rate (ECAR) ratio of CD11b+ cells in tumors, but not in the spleen. In addition, decreased reactive oxygen species (ROS) production and proton leakage in MDSCs and TAMs were consistently observed in tumors. Uptake of both 2-deoxy-2-d-glucose (2-NBDG) and BODIPY® decreased in MDSCs, but only BODIPY® incorporation was decreased in TAMs. Overall, our results suggest that Met redirects the metabolism of CD11b+ cells to lower oxidative phosphorylation (OXPHOS) while elevating glycolysis, thereby pushing the microenvironment to a state that inhibits the growth of certain tumors.

23 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
TFTomohiro Fujiwara
Tomohiro Fujiwara
KUKoji Uotani
Koji Uotani
AYAki Yoshida
Aki Yoshida
TMTakuya Morita
Takuya Morita
YNYutaka Nezu
Yutaka Nezu
TOToshifumi Ozaki
Toshifumi Ozaki
Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma Clinical significance of circulating miR-25-3p as a novel diagnostic and prognostic biomarker in osteosarcoma

1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
TUTakenori Uehara
Takenori Uehara
TFTomohiro Fujiwara
Tomohiro Fujiwara
KTKen Takeda
Ken Takeda
TKToshiyuki Kunisada
Toshiyuki Kunisada
TOToshifumi Ozaki
Toshifumi Ozaki
Heiichiro  UdonoHeiichiro Udono
Heiichiro Udono
Although multimodal therapies including surgery, chemotherapy, and radiotherapy have improved clinical outcomes of patients with bone and soft tissue sarcomas, the prognosis of patients has plateaued over these 20 years. Immunotherapies have shown the effectiveness for several types of advanced tumors. Immunotherapies, such as cytokine therapies, vaccinations, and adoptive cell transfers, have also been investigated for bone and soft tissue sarcomas. Cytokine therapies with interleukin-2 or interferons have limited efficacy because of their cytotoxicities. Liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE), an activator of the innate immune system, has been approved as adjuvant therapeutics in combination with conventional chemotherapy in Europe, which has improved the 5-year overall survival of patients. Vaccinations and transfer of T cells transduced to express chimeric antigen receptors have shown some efficacy for sarcomas. Ipilimumab and nivolumab are monoclonal antibodies designed to inhibit immune checkpoint mechanisms. These antibodies have recently been shown to be effective for patients with melanoma and also investigated for patients with sarcomas. In this review, we provide an overview of various trials of immunotherapies for bone and soft tissue sarcomas, and discuss their potential as adjuvant therapies in combination with conventional therapies.

1 April 2018 in Human Cell
Verified
Journal Article
Closed access
PDF file
FKFusako Kito
Fusako Kito
RORieko Oyama
Rieko Oyama
YTYoko Takai
Yoko Takai
MSMarimu Sakumoto
Marimu Sakumoto
KSKumiko Shiozawa
Kumiko Shiozawa
Tadashi KondoTadashi Kondo
Tadashi Kondo

8 December 2023 in Injury
Verified
Journal Article
Closed access
SFShiro Fukuoka
Shiro Fukuoka
MYMasanori Yorimitsu
Masanori Yorimitsu
TUTakenori Uehara
Takenori Uehara
SNShuichi Naniwa
Shuichi Naniwa
THToshiaki Hata
Toshiaki Hata
TOToshifumi Ozaki
Toshifumi Ozaki